Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A ten week, blinded trial of vitamin D vs. placebo in 80 patients with schizophrenia or
schizoaffective disorder who have low blood levels of vitamin D and elevated blood levels of
the amino acid proline. The aims of the study are to evaluate an anticipated clinical
response to vitamin D supplementation including negative symptoms and cognitive deficits,
evaluate safety of vitamin D supplementation for schizophrenia patients and evaluate the
relationship of changes in plasma proline levels and efficacy outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Columbia University Stanley Medical Research Institute
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins